{"id":15837,"date":"2021-11-03T08:49:51","date_gmt":"2021-11-03T08:49:51","guid":{"rendered":"https:\/\/clinlabint.com\/?p=15837"},"modified":"2021-11-03T08:49:51","modified_gmt":"2021-11-03T08:49:51","slug":"bio-rad-introduces-cfx-opus-dx-real-time-pcr-detection-systems-for-in-vitro-diagnostics","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/bio-rad-introduces-cfx-opus-dx-real-time-pcr-detection-systems-for-in-vitro-diagnostics\/","title":{"rendered":"Bio-Rad introduces CFX Opus Dx Real-Time PCR detection systems for In Vitro Diagnostics"},"content":{"rendered":"
\n

\r\n\"Bio-Rad<\/a>\r\n<\/p>\n<\/div><\/section><\/div>

<\/p>\n<\/div><\/section>
\n

Bio-Rad introduces CFX Opus Dx Real-Time PCR detection systems for In Vitro Diagnostics<\/h1>\/ in Product News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

Bio-Rad Laboratories, a global leader of life science research and clinical diagnostic products, has launched the CFX\u2122 Opus 96 Dx System and the CFX\u2122 Opus 384 Dx System, real-time PCR detection systems that have been listed with the U.S. Food and Drug Administration (FDA) for IVD testing and that meet the CE-IVD requirement for IVD use in Europe. Both systems are also registered with regulatory bodies for IVD use in Singapore and Canada.<\/strong><\/p>\n

<\/p>\n

The CFX Opus 96 Dx System and the CFX Opus 384 Dx System are the latest additions to Bio-Rad\u2019s portfolio of real-time PCR instruments. The systems offer accurate and precise quantification to improve assay development and workflow efficiencies and productivity for diagnostic testing and research. The CFX Opus 96 Dx<\/p>\n

Real-Time PCR System and the CFX Opus 384 Dx Real-Time PCR System are open systems that can multiplex up to five targets to provide efficient IVD assay development and testing. The systems provide precise quantification, improved thermal cycler performance, and the systems offer easyto-use desktop management and analysis software with integrated security features.<\/p>\n

\u201cWe continue to see an increasing demand for real-time PCR systems that offer more efficient workflows and improved data management and analysis that meets regulatory requirements in IVD assay development and testing, and we\u2019re pleased to introduce the CFX Opus Dx Detection Systems to meet these needs,\u201d said Steven Blakely, Director for Gene Expression and Software Technology, Bio-Rad. \u201cBoth systems are robust and secure platforms that leverage Bio-Rad\u2019s long-standing expertise in genomic tools to better serve both research and clinical diagnostic markets.\u201d<\/p>\n<\/div><\/section>
\n

\n